Shock arrest of ex-royal dominated British papers with one picture of the former prince, looking shellshocked in the back seat of a car, splashed across front pages The ramifications of Andrew Mountbatten-Windsor’s relationship with convicted sex offender Jeffrey Epstein escalated dramatically on Thursday, with the former prince arrested on suspicion of misconduct in public office. The arrest, rel...
Shock arrest of ex-royal dominated British papers with one picture of the former prince, looking shellshocked in the back seat of a car, splashed across front pages The ramifications of Andrew Mountbatten-Windsor’s relationship with convicted sex offender Jeffrey Epstein escalated dramatically on Thursday, with the former prince arrested on suspicion of misconduct in public office. The arrest, related to allegations that Andrew shared confidential material with Epstein, is an unprecedented nadir for the modern monarchy. Continue reading...
Kelvn | Istock | Getty Images Shares of Japanese drugmaker Sumitomo Pharma fell over 12% Friday on what appeared to be profit-taking, a day after the government endorsed the company's iPS cell-based therapy for Parkinson's and heart disease. The decision is a milestone in Japan's years-long effort to cultivate a homegrown sector focused on cutting-edge cellular therapies. Sumitomo Pharma's stock, ...
Kelvn | Istock | Getty Images Shares of Japanese drugmaker Sumitomo Pharma fell over 12% Friday on what appeared to be profit-taking, a day after the government endorsed the company's iPS cell-based therapy for Parkinson's and heart disease. The decision is a milestone in Japan's years-long effort to cultivate a homegrown sector focused on cutting-edge cellular therapies. Sumitomo Pharma's stock, which rose more than 300% in 2025, hit its highest level since 2019 last week amid growing confidence in its Parkinson's therapy. Citigroup Global Markets Japan's analyst Hidemaru Yamaguchi said that while the treatment might see widespread use and become a blockbuster in Japan and the U.S. over the long term, it would hardly contribute to profits in the near term. Sumitomo's stock has been overheated, and recent gains have been "excessive," he added. According to Japan's Ministry of Health, Labor and Welfare, formal approval will be granted within the next one to two months, NHK reported. Sumitomo Pharma develops and markets prescription medicines across multiple therapeutic areas, including neuroscience, oncology and regenerative medicine.
The dollar is poised to notch its best week in four months as traders pare back expectations for Federal Reserve interest-rate cuts while geopolitical risks boost the currency’s haven appeal. The Bloomberg Dollar Spot Index has climbed 0.9% this week, set for its biggest gain since October. Heightened inflation concerns and recent US economic data have clouded the outlook for Fed easing this year,...
The dollar is poised to notch its best week in four months as traders pare back expectations for Federal Reserve interest-rate cuts while geopolitical risks boost the currency’s haven appeal. The Bloomberg Dollar Spot Index has climbed 0.9% this week, set for its biggest gain since October. Heightened inflation concerns and recent US economic data have clouded the outlook for Fed easing this year, buoying the US currency. A continued buildup of US forces in the Persian Gulf has also burnished the appeal of the dollar, a popular destination during uncertain times. “Markets are shifting towards a higher probability of US and Iranian engagement,” said Richard Cochinos , a currency strategist at RBC Capital Markets. “The upward pressure on oil really keeps the euro and the Japanese yen from being seen as a safe haven, so the dollar steps in to fill that void.” The yen has fallen more than 1% during the week to trade close to 155 per dollar. The euro has dropped 0.9% over the period to $1.1758. The dollar has been under pressure in recent months as other major central banks held rates steady or signaled hikes, while the Fed was seen delivering further cuts — a view bolstered by President Donald Trump’s nomination of Kevin Warsh to become the next Fed chair. Uncertainty over US trade policy also weighed on the greenback, which saw its biggest drop in eight years in 2025. Wary Fed Minutes from the Fed’s latest meeting, however, revealed that officials were surprisingly wary of cutting interest rates when they met last month, with several suggesting the central bank may need to eventually raise borrowing costs if inflation remains stubbornly high. Later in the week, a run of economic data — including a steep drop in jobless claims — further undermined the case for reducing rates aggressively. Traders were pricing in about 58 basis points of cuts for this year, compared to 63 basis points at the end of last week. Read more: US Amasses Forces as Trump Says Iran Has Just Days ...
Earnings Call Insights: GRAIL, Inc. (GRAL) Q4 2025 Management View CEO Robert Ragusa reported "2025 was a year of significant commercial growth for GRAIL," highlighting the issuance of top line results from the NHS-Galleri trial, which showed "a substantial reduction in Stage IV cancer diagnosis, increased Stage I and II detection of deadly cancers and a fourfold higher cancer detection rate." Whi...
Earnings Call Insights: GRAIL, Inc. (GRAL) Q4 2025 Management View CEO Robert Ragusa reported "2025 was a year of significant commercial growth for GRAIL," highlighting the issuance of top line results from the NHS-Galleri trial, which showed "a substantial reduction in Stage IV cancer diagnosis, increased Stage I and II detection of deadly cancers and a fourfold higher cancer detection rate." While the trial did not meet its primary endpoint of statistically significant reduction in combined Stage III and IV diagnoses, Ragusa indicated these outcomes demonstrate the benefit of multi-cancer screening with Galleri. Ragusa announced a "planned expansion of our field sales and medical team" to capitalize on strong trial results, and confirmed the completion of GRAIL's PMA submission with the FDA for Galleri. He also noted the passage of the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, which "establishes a Medicare coverage pathway for FDA-approved multi-cancer early detection tests." Chief Scientific Officer Harpal Kumar described the NHS-Galleri trial as showing "more than 20% reduction in the second and third rounds" of Stage IV diagnoses in the prespecified group of 12 deadly cancers, and a "fourfold improvement in cancer detection rate compared to standard of care." Kumar emphasized the safety profile, saying "no serious safety concerns were reported in any of the approximately 70,000 participants who received the Galleri test across 3 rounds of testing." President Joshua Ofman stated the PMA submission was supported by data from two large registrational studies, including a "bridging analysis to compare performance of the version of Galleri used in our registrational trials to the updated version that has been submitted to the FDA for premarket approval." CFO Aaron Freidin reported "revenue of $43.6 million, up $5.3 million or 14% as compared to Q4 2024," with screening revenue comprising $42.3 million and development services...
The 18-year ordeal of Norida Akmal Ayob, 45, has cast a spotlight on a silent crisis: an unknown number of Malaysian women remain stranded in “dire straits” across Indonesia, unable to afford the journey home. According to Kosmo, many of these women share a similar trajectory – falling into financial ruin after marrying local men in Lombok and finding themselves trapped by the high costs of retur...
The 18-year ordeal of Norida Akmal Ayob, 45, has cast a spotlight on a silent crisis: an unknown number of Malaysian women remain stranded in “dire straits” across Indonesia, unable to afford the journey home. According to Kosmo, many of these women share a similar trajectory – falling into financial ruin after marrying local men in Lombok and finding themselves trapped by the high costs of returning home. “Money remains the main factor, as earning is difficult. My children and I were at the...
Intel (Ondo Tokenized), ticker symbol INTCON, is a tokenised security representing one share of Intel Corporation Common Stock (INTC). Issued by Ondo Finance, the token exists on supported blockchains and is backed 1:1 by the underlying equity held in custody. INTCON is part of a broader set of tokenised assets that provide onchain access to traditional financial instruments.
Intel (Ondo Tokenized), ticker symbol INTCON, is a tokenised security representing one share of Intel Corporation Common Stock (INTC). Issued by Ondo Finance, the token exists on supported blockchains and is backed 1:1 by the underlying equity held in custody. INTCON is part of a broader set of tokenised assets that provide onchain access to traditional financial instruments.
Newmont Corp. sent Barrick Mining Corp. a so-called notice of default after finding evidence of alleged mismanagement at a Nevada joint venture, escalating tensions between the partners in a key mining region. Barrick allegedly diverted resources from the venture, Nevada Gold Mines, or NGM, to benefit its wholly-owned Fourmile project, Denver-based Newmont said in a filing to the US Securities and...
Newmont Corp. sent Barrick Mining Corp. a so-called notice of default after finding evidence of alleged mismanagement at a Nevada joint venture, escalating tensions between the partners in a key mining region. Barrick allegedly diverted resources from the venture, Nevada Gold Mines, or NGM, to benefit its wholly-owned Fourmile project, Denver-based Newmont said in a filing to the US Securities and Exchange Commission on Thursday. After informing Barrick of the alleged issue last month, Newmont sent Barrick the notice in early February, the filing said. Under the companies’ 2019 joint-venture agreement , a partner accused of breaching the pact typically has 30 days to remedy the issue or begin corrective action. If a dispute isn’t resolved, it may be taken to court in Nevada, according to the agreement. “While we disagree with Newmont’s claims, we are limited by the terms of the joint venture agreement in what we can say,” Barrick President and Chief Executive Officer Mark Hill said in a statement to Bloomberg News. “We are committed to constructive engagement and to working together with Newmont to deliver shareholder value.” The intervention by Newmont may complicate Barrick’s plans to separate its North American assets and sell a 10% to 15% stake in the new company later this year. A spinoff would include its interest in NGM — of which Barrick owns 61.5% and Newmont 38.5% — along with the Fourmile project and a mine in the Dominican Republic, another joint venture with Newmont. Newmont wants Barrick to address what it sees as underperformance at the Nevada assets before going ahead with the IPO, Bloomberg News reported last week, citing people familiar with the matter. The miner has been critical of Barrick’s management after output declines and rising costs, the people said. In its 10-K filing to the SEC, Newmont said: “Although we continue to work with Barrick to improve the performance of NGM and will take appropriate steps to address this matter, any such disa...